You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 31, 2024

Details for Patent: 10,449,146


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,449,146 protect, and when does it expire?

Patent 10,449,146 protects KYNMOBI and is included in one NDA.

This patent has seven patent family members in four countries.

Summary for Patent: 10,449,146
Title:Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
Abstract: Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an "off" episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g.times.mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.
Inventor(s): Barnhart; Scott David (York, PA), Koons; Michael Clinton (York, PA), Hariharan; Madhu Sudan (Greensboro, NC), Dubow; Jordan (Glencoe, IL), Bilbault; Thierry (Toronto, CA), Giovinazzo; Anthony John (Caledon, CA)
Assignee: Sunovion Pharmaceuticals Inc. (Marlborough, MA)
Application Number:15/789,528
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 10,449,146

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-001 May 21, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-002 May 21, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-003 May 21, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-004 May 21, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-005 May 21, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.